# EDGAR Filing Document

**Accession Number:** 0001941029
**File Stem:** 0001213900-25-093917
**Filing Date:** 2025-9
**Character Count:** 4859
**Document Hash:** fc943927faa8f97bae2562d9734962b4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-093917.hdr.sgml**: 20250930

**ACCESSION NUMBER**: 0001213900-25-093917

**CONFORMED SUBMISSION TYPE**: NT 10-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250930

**DATE AS OF CHANGE**: 20250930

**EFFECTIVENESS DATE**: 20250930

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Advanced Biomed Inc.
- **CENTRAL INDEX KEY:** 0001941029
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** NV

**FILING VALUES:**
- **FORM TYPE:** NT 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42548
- **FILM NUMBER:** 251360319

**BUSINESS ADDRESS:**
- **STREET 1:** 401 RYLAND ST
- **STREET 2:** STE 200-A
- **CITY:** RENO
- **STATE:** NV
- **ZIP:** 89502
- **BUSINESS PHONE:** 86-21-20510823

**MAIL ADDRESS:**
- **STREET 1:** 401 RYLAND ST
- **STREET 2:** STE 200-A
- **CITY:** RENO
- **STATE:** NV
- **ZIP:** 89502

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON D.C. 20549**

**FORM 12b-25**

**NOTIFICATION OF LATE FILING**

SEC File Number 001-42548

(Check One) ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

For Period Ended: <u>June 30, 2025</u>

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

For the Transition Period Ended: ________________________

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I - REGISTRANT INFORMATION**

**<u>Advanced Biomed Inc.</u>**

Full Name of Registrant

**<u>N/A</u>**

Former Name if Applicable

<u>No. 689-85 Xiaodong Road, Yongkang District</u>

Address of Principal Executive Office (Street and Number)

<u>Tainan City, Taiwan 71052</u>

City, State, Zip Code

**PART II - RULES 12b-25(b) AND (c)**

&nbsp;&nbsp;&nbsp;&nbsp;(a) The reason described in reasonable
detail in Part III of this form could not be eliminated without unreasonable effort or expense;

☒ (b) The subject annual report, semi-annual report, transition
report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar
day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report
on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

&nbsp;&nbsp;&nbsp;&nbsp;(c) The accountant's statement or other exhibit required
by Rule 12b-25(c) has been attached if applicable.

**PART III - NARRATIVE**

**State below in reasonable detail why the Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR or the transition report portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if needed.)**

The Registrant is unable to file its Form 10-K Annual Report for the period ended June 30, 2025, within the prescribed time period without unreasonable effort or expense, as the audit of its financial statements has not yet been completed. The Registrant anticipates that the Form 10-K Annual Report, together with the financial statements, will be filed within the prescribed extension period.

**PART IV - OTHER INFORMATION**

(1) Name and telephone number of person to contact in regard to this notification:

<u>Fang Liu</u> <u>(703)</u> <u>919-7285</u> <br> Name Area Code Telephone

(2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). ☒ Yes ☐ No

(3) Is it anticipated that any significant change in results of operations
 from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject
 report or portion thereof? ☐ Yes ☒ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

**<u>Advanced Biomed Inc.</u>**

(Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| Date: September 30, 2025 | Date: September 30, 2025 |
| By: | /s/ Yi Lu |
| Name: | Yi Lu |
| Title: | Chief Executive Officer |

---